Announcements Trials
Browse Landscape

Status

Completed 7Terminated 3Recruiting 3Withdrawn 1Unknown 1Not yet recruiting 1No longer available 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Multiple Myeloma 15Melanoma 14Carcinoma, Non-Small-Cell Lung 13Recurrence 12Neoplasms 12Leukemia, Myeloid, Acute 9Glioblastoma 8Prostatic Neoplasms 6Lung Neoplasms 6Breast Neoplasms 6Lymphoma 5Glioma 5Carcinoma, Renal Cell 5Sarcoma 4Pancreatic Neoplasms 4Lymphoma, Non-Hodgkin 4Gastrointestinal Stromal Tumors 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Carcinoma 3Solid Tumors 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms by Site 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Anaplastic 2Liver Neoplasms 2Leukemia 2

Interventions

nilotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × INDUSTRY × Leukemia, Myeloid, Accelerated Phase × Clear all
NCT00413270 2011-07-13

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Novartis

No longer available
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡